Cellectar Biosciences, Inc. (NASDAQ:CLRB) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price target of $3.10 for the company, according to Zacks. Zacks has also assigned Cellectar Biosciences an industry rank of 181 out of 265 based on the ratings given to its competitors.
Several research firms have issued reports on CLRB. Zacks Investment Research cut Cellectar Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. ValuEngine raised Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
Shares of Cellectar Biosciences (CLRB) traded down $0.03 during trading on Tuesday, reaching $1.24. The company had a trading volume of 181,348 shares, compared to its average volume of 402,858. Cellectar Biosciences has a 52-week low of $1.12 and a 52-week high of $3.07.
Cellectar Biosciences (NASDAQ:CLRB) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). analysts forecast that Cellectar Biosciences will post -0.96 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by Week Herald and is the property of of Week Herald. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://weekherald.com/2017/12/08/zacks-analysts-set-3-10-price-target-for-cellectar-biosciences-inc-clrb.html.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.